Mersana Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Find out what a historical investment in Mersana Therapeutics Inc would be worth today using our MRSN stock calculator.
$39.74M
-
0.00%
1.21M
$0.35
$0.32
$0.32
$2.88
$0.26
Ready to start your investing journey with Stake?
Open an accountMRSN FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in MRSN
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in MRSN
on Stake
Buy MRSN from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of MRSN from only US$10 with fractional shares
